India imposes price caps on 36 more drugs | Device facilitates rapid delivery of stem cells into the heart | Scientists develop stem cell paste that could help repair bones
Web Version
September 23, 2014
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science

Top Story
India imposes price caps on 36 more drugs
India's National Pharmaceutical Pricing Authority added 36 drugs, including treatments for infections and diabetes, to its list of essential medicines that are subject to price controls. One of the drugs included in the latest price cap is ciprofloxacin, and the price cap would reduce the antibiotic's market value by about half, research firm AIOCD Pharmasofttech AWACS said. Reuters (9/19)
Share: LinkedInTwitterFacebookGoogle+Email
Device facilitates rapid delivery of stem cells into the heart
Doctors at the University of Frankfurt's German Cardiology Center have used TRI Medical's ND Infusion Catheter to rapidly and safely deliver stem cells into the heart. The catheter has a balloon that adjusts depending on the size of the blood vessel and stops blood flow while the stem cells are infused. The cells flow evenly to multiple tubes inside the catheter to prevent them from clumping, without causing physical stress that can affect the cells. (9/19)
Share: LinkedInTwitterFacebookGoogle+Email
Scientists develop stem cell paste that could help repair bones
Researchers at the University of Nottingham are developing a pastelike material that consists of hollow spheres of calcium phosphate packed with stem cells that could help new bone to develop. The process would involve extracting stem cells from a patient's bone marrow and combining them with the microspheres before infusing the material into the thinning bones so that the stem cells get to the damaged areas to promote repair. The Telegraph (London) (tiered subscription model) (9/21)
Share: LinkedInTwitterFacebookGoogle+Email
Asia Pacific
Hunter: What Modi must do to draw more investment to India
The Indian government will have to address the country's low health care spending, unpredictable regulatory system and antipathy toward intellectual property rights if Prime Minister Narendra Modi is serious about drawing greater investment to the biopharmaceutical sector and other knowledge-intensive industries, writes Rod Hunter, senior vice president of the Pharmaceutical Research and Manufacturers of America. India will benefit from greater prosperity, more economic opportunity and more investment if Modi succeeds in translating rhetoric into reality, Hunter writes. Hindustan Times (India) (9/18)
Share: LinkedInTwitterFacebookGoogle+Email
North America
Experts push Congress to pass bill to hasten antibiotic development
Following President Barack Obama's plan to launch a task force against antibiotic resistance, drug companies and health experts urged Congress to pass a bill that would create a pathway for the prompt development and approval of new antibiotics for limited populations based on smaller clinical trials. While the Antibiotic Development to Advance Patient Treatment Act, or ADAPT, does just that, some experts say the bill could affect patient safety. However, focusing on studies that specifically identify patients with resistant pathogens will allow for safer and faster smaller studies, experts say. Yahoo/Reuters (9/19)
Share: LinkedInTwitterFacebookGoogle+Email
Anti-obesity bill to boost access to drugs, counseling
U.S. Reps. Bill Cassidy, R-La., and Ron Kind, D-Wis., have introduced the Treat and Reduce Obesity Act meant to increase access to weight-loss counseling and new obesity drugs for Medicare beneficiaries. The legislation would also make incentives available to innovative biopharmaceutical firms. The Hill/Congress Blog (9/19)
Share: LinkedInTwitterFacebookGoogle+Email
Health care sector fighting war over drug prices
The costs of new specialty drugs are sparking criticism from insurers and pharmacy benefit managers, as well as suggestions that unsustainable prices could lead to government intervention, Philip Klein writes. Price controls would stifle innovation and the promise of new cures, said Lori Reilly, vice president for policy and research at Pharmaceutical Research and Manufacturers of America. "We're never going to get there if we have price controls in effect or if we send chilling signals to pharmaceutical companies that we're not going to value innovation when innovation happens," she said. The Examiner (Washington, D.C.) (9/22)
Share: LinkedInTwitterFacebookGoogle+Email
Irish university, Mayo Clinic collaborate on stem cell projects
The Mayo Clinic and the National University of Ireland, Galway, have agreed to work together on several regenerative medicine projects. The research topics will include adult stem cell treatments as well as gene therapies and biomedical and biomaterial engineering. The Irish Times (Dublin) (9/19)
Share: LinkedInTwitterFacebookGoogle+Email
Report: Global orthopedic-power-tools market could hit $1.6B in 2020
A MarketOptimizer report forecasts that the worldwide market for orthopedic power tools will increase from $1.4 billion in 2013 to $1.6 billion by 2020, with the fastest growth expected to come from India and China. The report cited Stryker, Medtronic, OsteoMed, Zimmer and DePuy Synthes as among the dominant market players. (9/18)
Share: LinkedInTwitterFacebookGoogle+Email
DIA News
Share knowledge and join the conversation with DIA
DIA has deeply grown into the patient community because we share the same mission: Improving research, discovery and development, and the delivery of safe and effective medical products to patients who need them. Bring patients into sharper focus by sharing knowledge and joining our conversations at:
Share: LinkedInTwitterFacebookGoogle+Email
It's not what you look at that matters, it's what you see."
-- Henry David Thoreau,
American writer and naturalist
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about DIA ->About DIA | Meetings & Trainings | News & Publications | Membership
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Lisa Gough
Advertising:  Meryl Harold
  P: 202.407.7828

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information